Search results for "Cancer development"

showing 10 items of 30 documents

T1078 The Validity of a Biomarker Method for Indirect Detection of Gastric Mucosal Atrophy Versus Standard Histopathology

2008

Background Atrophy of the stomach mucosa is considered to be premalignant lesion for gastric cancer development; easy identification of this condition from a blood-sample would allow identifying the group of individuals at increased risk for cancer development.

medicine.medical_specialtyPathologyHepatologybiologybusiness.industryAtrophic gastritisdigestive oral and skin physiologyGastroenterologymedicine.diseaseGastroenterologyIncreased riskAtrophyPepsinInternal medicinemedicinebiology.proteinBiomarker (medicine)HistopathologyCancer developmentbusinessGastric mucosal atrophyGastroenterology
researchProduct

Depleted uranium induces human carcinogenesis involving the immune and chaperoning systems: Realities and working hypotheses

2019

Abstract Cancer is caused by a combination of factors, genetic, epigenetics and environmental. Among the latter, environmental pollutants absorbed by contact, inhalation, or ingestion are major proven or suspected culprits. Depleted uranium (DU) is one of them directly pertinent to the military and civilians working in militarized areas. It is considered a weak carcinogen but its implication in cancer development in exposed individuals is supported by various data. Since not all subjects exposed to DU develop cancer, it is likely that DU-dependent carcinogenesis requires cofactors, such as genetic predisposition and deficiencies of the chaperoning and immune systems. It is of the essence to…

0301 basic medicineNeoplasms Radiation-InducedCarcinogenesisNatural killer cellPreventive measureWorking hypothesisBioinformaticsmedicine.disease_causeRisk AssessmentEpigenesis Genetic03 medical and health sciences0302 clinical medicineImmune systemOccupational ExposureGenetic predispositionmedicineHumansBone marrowDepleted uraniumSkinAir PollutantsChaperoning systemCarcinogenic cofactorbusiness.industryGenetic predispositionMicrobiotaMedicine (all)CancerEnvironmental ExposureGeneral MedicineArmed ConflictsModels Theoreticalmedicine.diseaseEnvironmental pollutantMilitary PersonnelImmune system030104 developmental biologyCarcinogensMolecular chaperoneUraniumEnvironmental PollutantsCancer developmentCarcinogenesisbusiness030217 neurology & neurosurgeryMolecular ChaperonesMedical Hypotheses
researchProduct

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

2016

Contains fulltext : 165965.pdf (Publisher’s version ) (Closed access) Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and speciali…

0301 basic medicineOncologymedicine.medical_specialtyEvidence-based practiceBevacizumabColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Guidelines as Topiccolorectal cancerRare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]03 medical and health scienceschemistry.chemical_compoundClinical practice guidelines; Colorectal cancer; Consensus; ESMO; Hematology; Oncology0302 clinical medicineGuia de Práctica ClínicaInternal medicineBiomarkers TumormedicineHumansMolecular Targeted TherapyNeoplasm MetastasisIntensive care medicineTipiracilNeoplasias Colorrectais/tratamentoFOLFOXIRIbusiness.industryESMO; clinical practice guidelines; colorectal cancer; consensusCancerHematologyESMOPrognosismedicine.diseaseDebulkingChemotherapy regimendigestive system diseases3. Good health030104 developmental biologyPractice GuidelineOncologychemistryColorectal Neoplasms/therapyconsensus030220 oncology & carcinogenesisColorectal Neoplasmsbusinessclinical practice guidelinesclinical practice guidelinemedicine.drug
researchProduct

Oral potentially malignant disorders: is malignant transformation predictable and preventable?

2014

Leukoplakia is the most common potentially malignant disorder of the oral mucosa. The prevalence is approximately 1% while the annual malignant transformation ranges from 2% to 3%. At present, there are no reliable clinicopathological or molecular predicting factors of malignant transformation that can be used in an individual patient and such event can not truly be prevented. Furthermore, follow-up programs are of questionable value in this respect. Cessation of smoking habits may result in regression or even disappearance of the leukoplakia and will diminish the risk of cancer development either at the site of the leukoplakia or elsewhere in the mouth or the upper aerodigestive tract. The…

medicine.medical_specialtyReferralOdontologíaReviewMalignant transformationSDG 3 - Good Health and Well-beingstomatognathic systemPredictive Value of TestsOral and maxillofacial pathologymedicineHumansOral mucosaGeneral DentistryLeukoplakiaOral Medicine and Pathologybusiness.industrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]DermatologyCiencias de la saludSurgerystomatognathic diseasesmedicine.anatomical_structureCell Transformation NeoplasticOtorhinolaryngologyPredictive value of testsUNESCO::CIENCIAS MÉDICAS/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSurgeryOral lichen planusMouth NeoplasmsCancer developmentLeukoplakia OralbusinessLichen Planus OralMedicina Oral Patologia Oral y Cirurgia Bucal
researchProduct

Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective …

2017

Abstract Introduction:Even in the era of novel targeted therapies for the treatment of Chronic Lymphocytic Leukemia (CLL) patients, such as BTK, PI3K and BCL2 inhibitors, allogeneic hematopoietic stem cell transplantations (alloHCT) will remain an important treatment option for a subset of patients with very high risk CLL. The current study focused on the impact of center and procedure-related factors on outcomes after alloHCT, taking into account the impact of patient- and disease-related risk factors. Patients and Methods:Data of 684 CLL patients who received a first alloHCT between 2000 and 2011 were analyzed. Their data were collected as part of the EBMT CLL Data Quality Initiative. Out…

OncologyMaleTransplantation ConditioningCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Chronic lymphocytic leukemiaMedizinQUALITY MANAGEMENT-SYSTEMKaplan-Meier Estimaterisk factor analysisGUIDELINESBiochemistryallogeneic stem cell transplantation; centre effects; chronic lymphocytic leukaemia; frailties; risk factor analysiscentre effectsTransplantation Conditioning / methods0302 clinical medicineRecurrenceRisk Factorsallogeneic stem cell transplantationLeukemia Lymphocytic Chronic B-Cell / mortalityRegistriesDelivery of Health Care / statistics & numerical dataIBRUTINIBddc:6160303 health sciencesALEMTUZUMABHazard ratioHematopoietic Stem Cell TransplantationProfessional PracticeHematologyMiddle Aged3. Good healthEurope030220 oncology & carcinogenesisABT-199CohortSURVIVALAlemtuzumabFemaleEurope / epidemiologymedicine.drugAdultmedicine.medical_specialtyAllogeneic transplantationImmunologyLower riskDIAGNOSISSettore MED/01 - Statistica Medica03 medical and health sciencesLeukemia Lymphocytic Chronic B-Cell / therapyHematopoietic Stem Cell Transplantation / methodsInternal medicinemedicineHumansKarnofsky Performance Status030304 developmental biologyAgedRetrospective Studiesbusiness.industryProportional hazards modelCHRONIC LYMPHOCYTIC-LEUKEMIARetrospective cohort studySTEM-CELL TRANSPLANTATIONCell Biologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellConfidence intervalSurgeryProfessional Practice / statistics & numerical dataTransplantationbusinessDelivery of Health Carefrailtieschronic lymphocytic leukaemia030215 immunologyRESPONSES
researchProduct

Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance.

2018

Cell-based assays to monitor antigen-specific T-cell responses are characterized by their high complexity and should be conducted under controlled conditions to lower multiple possible sources of assay variation. However, the lack of standard reagents makes it difficult to directly compare results generated in one lab over time and across institutions. Therefore TCR-engineered reference samples (TERS) that contain a defined number of antigen-specific T cells and continuously deliver stable results are urgently needed. We successfully established a simple and robust TERS technology that constitutes a useful tool to overcome this issue for commonly used T-cell immuno-assays. To enable users t…

0301 basic medicineRNA StabilityComputer scienceT cellPerformanceCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]RNA StabilityT-LymphocytesImmunologyCell Culture TechniquesComputational biology03 medical and health sciences0302 clinical medicineAll institutes and research themes of the Radboud University Medical CenterHigh complexityValidationHLA-A2 AntigenmedicineImmunology and AllergyHumansImrnunoguidingRNA MessengerCell EngineeringT-cell assaysReceptors Chimeric AntigenImmunomagnetic SeparationElectroporationT-cell receptorRNAReference StandardsStandardizationImmunomonitoring030104 developmental biologymedicine.anatomical_structureElectroporationBlood Buffy CoatFeasibility StudiesBiological Assay030215 immunologyJournal of immunological methods
researchProduct

Smart inulin-based polycationic nanodevices for siRNA delivery

2017

The advances of short interfering RNA (siRNA) mediated therapy provide a powerful option for the treatment of many diseases by silencing the expression of targeted genes including cancer development and progression. Inulin is a very simple and biocompatible polysaccharide proposed by our groups to produce interesting delivery systems for Nucleic Acid Based Drugs (NABDs), such as siRNA, either as polycations able to give polyplexes and polymeric coatings for nanosystems having a metallic core. In this research field, different functionalizing groups were linked to the inulin backbone with specific aims including oligoamine such as Ethylendiammine (EDA), Diethylediamine (DETA), Spermine, (SPM…

3003Small interfering RNABiocompatibilitysiRNA complexing abilityInulinPharmaceutical ScienceSpermineNanotechnology02 engineering and technology010402 general chemistry01 natural scienceschemistry.chemical_compoundDrug Delivery SystemsPolyaminesBiocompatibility; Silencing ability; siRNA complexing ability; 3003HumansNanotechnologyGene silencingRNA Small InterferingChemistryInulin021001 nanoscience & nanotechnologyPolyelectrolytes0104 chemical sciencesBiochemistryNucleic acidBiocompatibilityCancer development0210 nano-technologySilencing abilityChemical design
researchProduct

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

2020

Contains fulltext : 218279.pdf (Publisher’s version ) (Open Access) Patients with acute myeloid leukemia (AML) harboring FLT3 internal tandem duplications (ITDs) have poor outcomes, in particular AML with a high (>/=0.5) mutant/wild-type allelic ratio (AR). The 2017 European LeukemiaNet (ELN) recommendations defined 4 distinct FLT3-ITD genotypes based on the ITD AR and the NPM1 mutational status. In this retrospective exploratory study, we investigated the prognostic and predictive impact of the NPM1/FLT3-ITD genotypes categorized according to the 2017 ELN risk groups in patients randomized within the RATIFY trial, which evaluated the addition of midostaurin to standard chemotherapy. The 4 …

OncologyPROBABILITIESMalePROGNOSISCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]NPM1 MUTATIONBiochemistryEuropean LeukemiaNetchemistry.chemical_compoundALLELIC RATIOAMLRisk FactorsGene Duplicationhemic and lymphatic diseasesMidostaurinFLT3Myeloid NeoplasiaHematopoietic Stem Cell TransplantationMyeloid leukemiaNuclear ProteinsHematologyCHEMOTHERAPYMiddle AgedPrognosisChemotherapy regimenEuropeLeukemia Myeloid Acutemedicine.anatomical_structureTreatment OutcomeTandem Repeat SequencesFemaleNucleophosminmedicine.medical_specialtyNPM1GenotypeImmunologyYOUNGER ADULTSInternal medicineWhite blood cellmedicineNORMAL CYTOGENETICSHumansGenetic Predisposition to DiseaseProportional Hazards ModelsProportional hazards modelbusiness.industryCell BiologyINTERNAL TANDEM DUPLICATIONTransplantationchemistryfms-Like Tyrosine Kinase 3Multivariate AnalysisbusinessSettore MED/15 - Malattie del Sangue
researchProduct

Metabolite Sensing GPCRs: Promising Therapeutic Targets for Cancer Treatment?

2020

G-protein-coupled receptors constitute the most diverse and largest receptor family in the human genome, with approximately 800 different members identified. Given the well-known metabolic alterations in cancer development, we will focus specifically in the 19 G-protein-coupled receptors (GPCRs), which can be selectively activated by metabolites. These metabolite sensing GPCRs control crucial processes, such as cell proliferation, differentiation, migration, and survival after their activation. In the present review, we will describe the main functions of these metabolite sensing GPCRs and shed light on the benefits of their potential use as possible pharmacological targets for cancer treat…

G-protein-coupled receptorMetaboliteReviewComputational biologyBiologyReceptors G-Protein-CoupledBile Acids and Saltschemistry.chemical_compoundNeoplasmsmetabolite sensing GPCRBiomarkers TumormedicinecancerAnimalsHumansMolecular Targeted TherapyAmino AcidsReceptorlcsh:QH301-705.5G protein-coupled receptorCell growthDisease ManagementCancerGeneral MedicineLipid Metabolismmedicine.diseaseCancer treatmentlcsh:Biology (General)Gene Expression RegulationchemistryHuman genomeDisease SusceptibilityCancer developmentEnergy MetabolismSignal TransductionCells
researchProduct

Female-specific association among I, J and K mitochondrial genetic haplogroups and cancer:A longitudinal cohort study

2018

Recent studies highlighted the role of mitochondrial dysregulation in cancer, suggesting that the different mitochondrial haplogroups might play a role in tumorigenesis and risk of cancer development. Our aim is to investigate whether any mitochondrial haplogroups carried a significant higher risk of cancer development in a large prospective cohort of North American people. The haplogroup assignment was performed by a combination of sequencing and PCR-RFLP techniques. Our specific outcome of interest was the incidence of any cancer during follow-up period. Overall, 3222 participants were included in the analysis. Women having I, J, K haplogroup reported a significant higher incidence of can…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtygenetic structuresBiologymedicine.disease_causeDNA MitochondrialHaplogroupHaplogroupArticleCohort Studies03 medical and health sciences0302 clinical medicineInternal medicineNeoplasmsGeneticsmedicineHumansGenetic Predisposition to DiseaseLongitudinal StudiesLongitudinal cohortProspective cohort studyMolecular BiologyOncogenesisCancerCancer Screening Oncogenesis Mitochondrial HaplogroupIncidence (epidemiology)Cancermedicine.diseaseeye diseaseshumanitiesMitochondrial030104 developmental biologyHaplotypes030220 oncology & carcinogenesisScreeningCancer; Haplogroup; Mitochondrial; Oncogenesis; ScreeningFemaleCancer developmentCarcinogenesis
researchProduct